Latest & greatest articles for lisdexamfetamine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lisdexamfetamine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lisdexamfetamine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lisdexamfetamine

1. Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V

Lisdexamfetamine (ADHD) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Lisdexamfetamindimesilat (Aufmerksamkeitsdefizit- Hyperaktivitätsstörung bei Erwachsenen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 July 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding (...) . IQWiG Reports – Commission No. A19-40 Lisdexamfetamine dimesylate (attention deficit/hyperactivity disorder in adults) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-40 Version 1.0 Lisdexamfetamine dimesylate (ADHD in adults) 30 July 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Lisdexamfetamine dimesylate (attention deficit/hyperactivity

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

2. Lisdexamfetamine

Lisdexamfetamine Top results for lisdexamfetamine - Trip Database or use your Google+ account Liberating the literature ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2 (...) ) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for lisdexamfetamine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms

2018 Trip Latest and Greatest

3. Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients

Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before (...) adding more. Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03070509 Recruitment Status : Recruiting First Posted : March 3, 2017 Last

2017 Clinical Trials

4. Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. Full Text available with Trip Pro

Patterns of Lisdexamfetamine Dimesylate Use in Children, Adolescents, and Adults with Attention-Deficit/Hyperactivity Disorder in Europe. Objectives: Lisdexamfetamine dimesylate (LDX) is approved in some European countries for the second-line treatment of attention-deficit/hyperactivity disorder (ADHD) in children and adolescents when response to previous methylphenidate (MPH) treatment is considered clinically inadequate, and as a first-line treatment in adults. Limited evidence exists

2020 Journal of Child and Adolescent Psychopharmacology

5. Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

Lisdexamfetamine Dimesylate for Preschool Children with Attention-Deficit/Hyperactivity Disorder. Objectives: Describe the safety and tolerability of lisdexamfetamine dimesylate (LDX) and provide data on clinical effects for efficacy-related endpoints and pharmacokinetics in preschool-aged children with attention-deficit/hyperactivity disorder (ADHD). Methods: This phase 2, multicenter, open-label, dose-optimization study (ClinicalTrials.gov registry: NCT02402166) was conducted at seven U.S

2020 Journal of Child and Adolescent Psychopharmacology

6. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate

Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate Attention deficit h Attention deficit hyper yperactivity disorder in activity disorder in children and y children and young people: lisde oung people: lisdexamfetamine xamfetamine dimesylate dimesylate Evidence summary Published: 7 May 2013 nice.org.uk/guidance/esnm19 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in May (...) 2013. See summaries of product characteristics (SPCs), British national formulary (BNF), BNF for children (BNFc) or the MHRA or NICE websites for up-to-date information. Summary Limited evidence from 1 RCT suggests that lisdexamfetamine dimesylate produces clinically meaningful benefits in ADHD symptoms compared with placebo. The adverse effect profile appears similar to other stimulant drugs, although theoretical advantages in terms of improved adherence and reduced abuse potential require further

2013 National Institute for Health and Clinical Excellence - Advice

7. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate Full Text available with Trip Pro

A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate An economic analysis from the perspective of the UK National Health Service (NHS) evaluated the cost effectiveness of lisdexamfetamine dimesylate (LDX) compared with atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder who have had an inadequate response

2016 CNS drugs

8. Lisdexamfetamine dimesylate (Elvanse Adult®)

Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) Lisdexamfetamine dimesylate (Elvanse Adult®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Lisdexamfetamine dimesylate (Elvanse Adult®) Penarth: All Wales Therapeutics and Toxicology (...) Centre (AWTTC), secretariat of the All Wales Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2534. 2015 Authors' conclusions Lisdexamfetamine dimesylate (Elvanse Adult®) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Adult; Attention Deficit Disorder with Hyperactivity

2015 Health Technology Assessment (HTA) Database.

9. Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD. (Abstract)

Effectiveness and Duration of Effect of Open-Label Lisdexamfetamine Dimesylate in Adults With ADHD. (a) Evaluate the efficacy and duration of effect of lisdexamfetamine dimesylate (LDX) in adult ADHD. (b) Assess the reliability and validity of the Adult ADHD Medication Smoothness of Effect Scale (AMSES) and Adult ADHD Medication Rebound Scale (AMRS).Adults ( N = 40) with ADHD were treated with LDX for up to 12 weeks. The primary efficacy measure was the ADHD Rating Scale (ADHD-RS

2017 Journal of attention disorders Controlled trial quality: uncertain

10. Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. Full Text available with Trip Pro

Clinical Characteristics and Treatment Response to Lisdexamfetamine Dimesylate Versus Placebo in Adults With Binge Eating Disorder: Analysis by Gender and Age. To describe clinical characteristics and lisdexamfetamine dimesylate (LDX) treatment effects, based on gender and age, in adults diagnosed with moderate to severe binge eating disorder (BED).Adults diagnosed with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision-defined BED of moderate to severe

2019 Journal of Clinical Psychiatry Controlled trial quality: uncertain

11. Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder Full Text available with Trip Pro

Review of Lisdexamfetamine Dimesylate in Adults With Attention-Deficit/Hyperactivity Disorder Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant used for the treatment of attention-deficit/hyperactivity disorder (ADHD) dosed once daily. Due to its long-acting properties, LDX remains pharmacologically inactive until an enzymatic process predominantly associated with red blood cells converts it to the active ingredient, d-amphetamine and the amino acid lysine. The efficacy of LDX (...) over placebo has been demonstrated in several studies in adults with moderate to severe ADHD with significant improvements noted in ADHD rating scales, Clinical Global Improvement scores, and assessments of executive function, for all doses of LDX (30-70 mg daily). Lisdexamfetamine dimesylate has demonstrated efficacy at 14 hours post dose in adults and may be used as a long-acting stimulant for managing ADHD symptoms, which may extend late into the day. Lisdexamfetamine dimesylate has demonstrated

2017 Journal of central nervous system disease

12. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder. Full Text available with Trip Pro

Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder. Objective: To further define the efficacy and safety profiles of lisdexamfetamine dimesylate (LDX) in Japanese pediatric patients with attention-deficit/hyperactivity disorder (ADHD). Methods: This was a multicenter, randomized, double-blind, placebo-controlled study of LDX 30, 50, or 70 mg/day for 4 weeks in 76 patients 6-17 years of age with ADHD in Japan

2020 Journal of Child and Adolescent Psychopharmacology

13. A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD

A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more (...) studies before adding more. A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02555150 Recruitment Status : Completed First Posted : September 21, 2015 Last Update Posted : January 19, 2017 Sponsor: Rhodes

2015 Clinical Trials

14. Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects

Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Lisdexamfetamine in Binge Eating (...) Collaborator: University of Cincinnati Information provided by (Responsible Party): Lindner Center of HOPE Study Details Study Description Go to Brief Summary: The purpose of this study is to explore the effect of Lisdexamfetamine on Prefrontal Brain Dysfunction in Binge Eating Disorder Condition or disease Intervention/treatment Phase Binge Eating Disorder Drug: Lisdexamfetamine Phase 2 Detailed Description: 12-week, open-label LDX trial for BED including fMRI assessments to test the following specific

2016 Clinical Trials

15. Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. Full Text available with Trip Pro

Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial. The ability of pharmacotherapies to prevent relapse and maintain efficacy with long-term treatment in psychiatric conditions is important.To assess lisdexamfetamine dimesylate maintenance of efficacy in adults with moderate to severe binge-eating disorder.A multinational, phase 3, double-blind, placebo-controlled, randomized withdrawal study including 418 participants was conducted (...) at 49 clinical research study sites from January 27, 2014, to April 8, 2015. Eligible adults met DSM-IV-R binge-eating disorder criteria and had moderate to severe binge eating disorder (≥3 binge-eating days per week for 14 days before open-label baseline; Clinical Global Impressions-Severity [CGI-S] scores ≥4 [moderate severity] at screening and open-label baseline). Following a 12-week, open-label phase (dose optimization, 4 weeks [lisdexamfetamine dimesylate, 50 or 70 mg]; dose maintenance, 8

2017 JAMA psychiatry (Chicago, Ill.) Controlled trial quality: predicted high

16. Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Open-Label Pilot Study (...) of Lisdexamfetamine for Cocaine Dependence (Vyvance) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01486810 Recruitment Status : Completed First Posted : December 7, 2011 Results First Posted : July 11, 2018 Last Update Posted : November 1, 2018 Sponsor: New York State Psychiatric Institute Collaborator

2011 Clinical Trials

17. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Full Text available with Trip Pro

Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. In clinical practice, α₂-adrenoceptor agonists have been adjunctively administered with psychostimulants for the treatment of attention-deficit/hyperactivity disorder (ADHD). Two studies have examined the adjunctive use of guanfacine extended release (GXR, Intuniv®; Shire Development LLC, Wayne, PA, USA) with psychostimulants in children and adolescents with a suboptimal response to psychostimulant (...) treatment. However, the potential for pharmacokinetic drug-drug interactions (DDIs) between GXR and lisdexamfetamine dimesylate (LDX, Vyvanse®; Shire US LLC, Wayne, PA, USA) has not been thoroughly evaluated.The primary objective of this study was to examine the pharmacokinetics of GXR 4 mg and LDX 50 mg given as single doses alone and in combination.This was an open-label, randomized, three-period crossover, DDI study.The study was conducted in a single clinical research center.Forty-two healthy adults

2013 Drugs in R&D Controlled trial quality: uncertain

18. Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder.

Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder. Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Lisdexamfetamine Dimesylate in Residual Symptoms and Cognitive Impairment in Major Depressive Disorder. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01148979 Recruitment Status : Completed First Posted : June 23, 2010 Results First Posted : May

2010 Clinical Trials

19. Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. (Abstract)

Lisdexamfetamine Targets Amygdala Mechanisms That Bias Cognitive Control in Attention-Deficit/Hyperactivity Disorder. Prefrontal-limbic circuits that form the neural architecture for emotion to influence behavior have been implicated in the pathophysiology of attention-deficit/hyperactivity disorder (ADHD) and represent a potentially important target of medication treatment that has not been substantively evaluated. This study tested the effect of the psychostimulant prodrug lisdexamfetamine (...) dimesylate on amygdala activation and connectivity during the emotional bias of response execution and inhibition.Twenty-five adults with ADHD were scanned twice with event-related functional magnetic resonance imaging while performing an emotional go/no-go task after 3 to 4 weeks of lisdexamfetamine treatment and 3 weeks off medication in a randomized, counterbalanced, hybrid crossover design. Drug, trial type, and face emotion (happy, sad, or neutral) were included as within-subjects factors

2018 Biological psychiatry. Cognitive neuroscience and neuroimaging Controlled trial quality: uncertain

20. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. (Abstract)

Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder. Lisdexamfetamine dimesylate is a stimulant prodrug with low abuse and diversion potential that is used in treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults. This current literature review article aims to examine safety and efficacy of LDX in children and adolescents for the treatment of ADHD based on currently available data.Relevant (...) English language articles were identified through computerized searches of the MEDLINE database (PubMed and EMBASE) and clinical trials registry up to January 2020 using the following search terms: lisdexamfetamine dimesylate, pro-drug stimulant, attention-deficit and hyperactivity disorders, ADHD, safety, efficacy, children, adolescents, Vyvanse. Forty-two articles were reviewed, 34 of which were included into this review, selected by the limit "clinical trials". This article represents

2020 Current medical research and opinion